Role of Chlorambucil in Combination or Not With Anti‐cd20 as Frontline Therapy in Chronic Lymphocytic Leukemia in "Real Life"

Abstract

cohort, suggesting potential overlap with immunodeficiency seen with CLL/SLL pts. Most surprisingly is the high rate of infusion related reactions; however, these were mainly confined to grade 2 reactions and grade 3 reactions were much lower than in the CLL11 trial (Goede V, NEJM 2014). While PFS is shorter compared to CLL11, this reflects both pts not completing therapy, as well as including pts in the r/r setting. Regardless, OBI remains an effective and well tolerated agent in both frontline and r/r pts with CLL/SLL who may not be eligible for other therapies.ABSTRACT 379